Emerging Targeted Therapies for Castration-Resistant Prostate Cancer

Until recently, few therapeutic options were available for patients with castration-resistant prostate cancer (CRPC). Since 2010, four new molecules with a demonstrated benefit (sipuleucel-T, cabazitaxel, abiraterone, and denosumab) have been approved in this setting, and to-date several other agent...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Adamo, Vincenzo, Noto, Laura, Franchina, Tindara, Chiofalo, Giuseppe, Picciotto, Maria, Toscano, Giuseppe, Caristi, Nicola
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Research Foundation 2012
Assuntos:
Endocrinology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3364443/
https://ncbi.nlm.nih.gov/pubmed/22666217
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2012.00073
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados